LAKEWOOD-AMEDEX BIOTHERAPEUT

Lakewood‑amedex Biotherapeut’s sharp 36.7% decline, 24‑hour trading volume, and market cap drop—see how peers performed and key price levels.

Lakewood‑Amedex Biotherapeutics drops nearly 19% as its $0.47 stock and $1.4 M cap reveal a risky biotech gamble lacking a clear pipeline and financial plan. Read more.

Lakewood‑amedex Biotherapeut (LABT) stays flat after a steep drop, trading at $0.52 with a low 200‑day moving average of $7.67—investors watch its biotech upside potential.